Mianserin - Medication and Pregnancy KB

Mianserin

Exposed non-exposed, cohort studies

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
Kjaersgaard 2013	Denmark 1997 - 2008 population based cohort retrospective	Danish administrative health registries.	Mother that had redeemed a prescription for Mianserin at any time from 30 days before conception up to 1 day before the end of pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed (general population or NOS) Mother that had not redeemed any prescription for antidepressant medication from 6 months before conception up to 1 day before the end of the pregnancy.	during pregnancy (anytime or not specified)	-9 / 983258	Molar or ectopic pregnancies (ICD-10: O00.0– O01.9) were excluded from the main analyses. Unexposed cohort: 1843 plus 981415 = 983258.
Kjaersgaard 2013	Denmark 1997 - 2008 population based cohort retrospective	Danish administrative health registries.	Information on all redeemed prescriptions was obtained from the Denmark Registry of Medicinal Product Statistics.		during pregnancy (anytime or not specified)	-9 / 983258
Yaris 2005	Turkey 1999 - 2004 prospective cohort	Toxicology Information and Follow-up Service	Women who were exposed to Mianserin during pregnancy for depression, anxiety, and psychotic disorders. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed (general population or NOS) Women who did not use any drug while pregnant.	during pregnancy (anytime or not specified)	5 / 248	Raw data for Intrauterine exitus not reported because the nb of cases in the unexposed group not clearly stated. Raw data for premature delivery not reported because the denominator is not clearly stated.
Yaris 2005	Turkey 1999 - 2004 prospective cohort	Toxicology Information and Follow-up Service	Data surveyed by the interviews.		during pregnancy (anytime or not specified)	5 / 248

Case-control studies

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;

Empty. There are no case-control studies available for this drug.

master protocol